Proteomics International Laboratories Ltd 2025 AR2
The report highlights Proteomics International Laboratories Ltd's transition from research and development to the commercialisation of its predictive diagnostic tests during the 2025 fiscal year. Key milestones include the launch of the PromarkerD test for diabetic kidney disease in Australia and the United States, alongside the opening of a CLIA-certified reference laboratory in California. The company also advanced its diagnostic pipeline, with PromarkerEndo for endometriosis and PromarkerEso for esophageal cancer nearing commercial availability. To support these rollouts, the company completed a successful 12 million AUD capital raise and secured a 6 million AUD funding boost to expand its WA Proteomics Facility.
Company: Proteomics International Laboratories Ltd
Sector: Professional & technical services
Country: Australia
Year: 2025
Type: AR2
Pages: 49
Back to company
Proteomics International Laboratories Ltd
Annual Report
The report highlights Proteomics International Laboratories Ltd's transition from research and development to the commercialisation of its predictive diagnostic tests during the 2025 fiscal year. Key milestones include the launch of the PromarkerD test for diabetic kidney disease in Australia and the United States, alongside the opening of a CLIA-certified reference laboratory in California. The company also advanced its diagnostic pipeline, with PromarkerEndo for endometriosis and PromarkerEso for esophageal cancer nearing commercial availability. To support these rollouts, the company completed a successful 12 million AUD capital raise and secured a 6 million AUD funding boost to expand its WA Proteomics Facility.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management